ImmunoPrecise Antibodies

ImmunoPrecise Antibodies (IPA) (now rebranded as MindWalk) offers bio-native AI solutions that pair a patented HYFT protocol with the proprietary LensAI platform. The result is rapid, efficient drug discovery and development that meets the needs of leading biotherapeutics companies. ImmunoPrecise Antibodies’ discovery capacities rely on a single computational language that is integrated with manufacturing at a full-stack wet lab. This gives it a unique status as a single-source provider of antibody discovery platforms.

ImmunoPrecise Antibodies’ complex, disruptive AI capacities include in silico machine intelligence that processes big data and provides sought-after pharmaceutical solutions. This population-scale biologics analytics approach enables it to address debilitating and potentially fatal conditions, including cancer, in the most impactful way possible.

ImmunoPrecise Antibodies’ transformative, pattern-seeking approach to therapeutics has earned it a reputation for cost-effectively delivering validated candidates. Team members are committed to identifying the right combination of species, immunogens, and immunization schedules to enable optimal patient outcomes.